The Department of Health – Abu Dhabi (DoH) and Novartis have announced the activation of the Abu Dhabi Clinical Trials Hub through global Phase 3 clinical trial programmes spanning neuroscience, cardiovascular disease, oncology and immunology.
Announced at Abu Dhabi Future Health Summit 2026, the milestone aims to connect the Emirate’s clinical research capabilities with international drug development programmes, creating opportunities for local investigators and eligible patients to participate in clinical studies.
The development builds on a Memorandum of Understanding signed by DoH and Novartis on 5 June 2024. Over the past two years, the collaboration has supported work across clinical research, evidence generation, healthcare innovation and research capability development.
Click here to join our WhatsApp channel here
The next phase will focus on strengthening investigator and research-site readiness, streamlining study initiation and improving pathways to identify and refer eligible participants. Individual studies and participating sites will remain subject to feasibility assessments and the required regulatory, ethics and institutional approvals.
Also read: Offshore Worker Survives Life-Threatening Heart Attack After Rapid Medical Evacuation
Mohamed Ezz Eldin, Head of Novartis GCC, said: “Research and development are at the heart of Novartis. Over the past two years, our collaboration with the Department of Health – Abu Dhabi has built a strong foundation for clinical research, site readiness and scientific capability. As we look ahead, we aim to connect Abu Dhabi’s strengths with our global research programmes, expand opportunities for patients to take part in high-quality clinical research, and support the next generation of investigators in the region. Together with our partners, we look forward to going further to advance health innovation.”
The collaboration reflects Abu Dhabi’s broader ambition to strengthen its life sciences ecosystem, support scientific exchange and increase participation in suitable regional and global clinical development programmes.
